Leukocytosis Market Report 2026

Leukocytosis Market Overview

• Leukocytosis market size has reached to $5.13 billion in 2025 • Expected to grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Rising Incidence Of Blood-Related Diseases Fueling The Growth Of The Market Due To Increasing Prevalence And Aging Populations • Market Trend: Advancements In AI-Powered Diagnostic Systems For Enhanced Disease Detection And Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leukocytosis Market?

Leukocytosis is a condition in which the white blood cell (WBC) count in the bloodstream is higher than usual. It often indicates an underlying infection, inflammation, or immune response. The primary purpose of treatment of this condition is to enhance the body's defense mechanisms by increasing the number of WBCs to fight infections or heal injuries. The main disease types in leukocytosis are infection, inflammation, leukemia, and stress response. Infections lead to leukocytosis as the immune system reacts to invading pathogens by increasing the production of white blood cells (WBCs), particularly neutrophils, to fight off bacterial threats. Diagnosis of leukocytosis involves blood tests, bone marrow biopsies, and imaging techniques. The condition is managed and treated through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies. Major end users of leukocytosis-related diagnostics and treatments include hospitals, diagnostic laboratories, and research institutions.

What Is The Leukocytosis Market Growth Forecast?

The leukocytosis market size is expected to see strong growth in the next few years. It will grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to advancements in hematology diagnostics, rising adoption of personalized treatment approaches, growing awareness of early disease detection, increasing healthcare expenditure, expansion of laboratory automation. Major trends in the forecast period include increasing adoption of advanced blood diagnostics, growing focus on underlying disease-specific treatment, rising use of precision medicine in hematology, expansion of automated and high-throughput testing, increasing integration of clinical decision support systems.

What Is The Driver Of The Leukocytosis Market?

The rising incidence of blood-related diseases is expected to propel the growth of the leukocytosis market going forward. Blood-related diseases are medical conditions that affect blood components, such as red blood cells, white blood cells, platelets, or plasma. The blood-related diseases are increasing due to aging populations, as older adults are more susceptible to conditions such as anemia, leukemia, and clotting disorders due to declining immune function and cumulative health issues. Blood-related diseases frequently result in elevated white blood cell counts, a characteristic sign of leukocytosis, highlighting the need for enhanced early diagnosis, improved monitoring tools, and more effective treatment options. For instance, in 2024, according to the American Cancer Society, a US-based cancer organization, there were 62,770 new cases of leukemia reported in 2024, a significant increase from 59,610 cases in 2023. Therefore, the rise in the incidence of blood-related diseases is driving the growth of the leukocytosis industry.

Key Players In The Global Leukocytosis Market

Major companies operating in the leukocytosis market are Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Roche Diagnostics AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis International AG, Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD), Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Agilent Technologies Inc., Grifols SA, Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Beckman Coulter Diagnostics Inc., Bio-Rad Laboratories, Bio-Techne Corporation, NeoGenomics Laboratories Inc., DiaSorin S.p.A.

Global Leukocytosis Market Trends and Insights

Major companies operating in the leukocytosis market are focusing on integrating artificial intelligence in diagnostic systems to enhance early detection, diagnostic accuracy, and personalized treatment planning. Artificial intelligence in diagnostic systems refers to the use of artificial intelligence (AI) technologies such as machine learning, deep learning, and natural language processing to analyze medical data and support or automate the diagnosis of diseases. For instance, in December 2024, Koninklijke Philips NV, a Netherlands-based healthcare company, launched the CT 5300 system. It integrates proprietary artificial intelligence (AI) technologies to enhance computed tomography (CT) imaging workflows. The system features the computed tomography smart workflow, incorporating artificial intelligence (AI)-driven tools such as precise position, precise cardiac, and precise brain, which streamline scan preparation, improve diagnostic accuracy, and reduce radiation exposure.

What Are Latest Mergers And Acquisitions In The Leukocytosis Market?

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. With this acquisition, AbbVie strengthens its oncology portfolio by integrating ImmunoGen's expertise in antibody-drug conjugates (ADCs), enhancing its ability to develop targeted therapies for blood-related cancers and conditions like leukocytosis. ImmunoGen Inc. is a US-based biotechnology company specializing in antibody-drug conjugates (ADCs) for treating blood-related cancers such as leukemia, which often cause leukocytosis.

What Defines the Leukocytosis Market?

The leukocytosis market includes revenues earned by entities through complete blood count (CBC) testing, white blood cell differential analysis, monitoring and management of underlying conditions, development and administration of targeted therapeutics, and support for clinical research and drug trials focused on hematologic abnormalities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukocytosis Market Report 2026?

The leukocytosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukocytosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.